|
FY
|
Partners
|
Title
|
|
2023
|
NEX-I
|
Ono Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101
|
|
AstraZeneca
|
Settlement Agreement over lawsuits on PD-L1 and CTLA-4 antibody patents with AstraZeneca
|
|
2022
|
Equillium
|
Ono and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
|
|
2020
|
Ribon Therapeutics
|
ONO enters into License Agreement with Ribon Therapeutics for the Development and Commercialization of RBN-2397, a PARP7 Inhibitor, in Japan, South Korea, Taiwan and ASEAN Countries
|
|
Chordia Therapeutics
|
ONO Enters into Exclusive License Agreement with Chordia Therapeutics on CTX-177, a MALT1 Inhibitor, and its Related Compounds(131 KB)
|
|
Roche
|
ONO and Bristol Myers Squibb Enter Patent License Agreement with Roche
|
|
SK Biopharmaceuticals
|
Ono Enters into License Agreement on Cenobamate, an Antiepileptic Drug with SK Biopharmaceuticals
|
|
2019
|
Nichi-Iko
|
ONO and Nichi-Iko Enter into Licensing Agreement and Technical Collaboration for Limaprost Alfadex Tablets
|
|
Forty Seven
|
ONO and Forty Seven, Inc. Sign a License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Other Selected Countries in Southeast Asia
|
|
Rafael Pharmaceuticals
|
ONO Enters into Exclusive License Agreement with Rafael Pharmaceuticals on CPI-613 (devimistat), a Cancer Metabolism Inhibitor, and Other Related Compounds
|
|
2017
|
Bristol-Myers Squibb
|
ONO Enters into License Agreement with Bristol-Myers Squibb for Prostaglandin E2 Receptor Antagonists relating to Immuno-Oncology Programs
|
|
Karyopharm
|
Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors
|
|
Seikagaku
|
Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan
|
|
Array Biopharma
|
ONO Concludes a License Agreement with Array Biopharma related to Binimetinib, a MEK inhibitor and Encorafenib, a BRAF inhibitor
|
|
2016
|
Merck
|
Ono Pharmaceutical Company and Bristol-Myers Squibb Enter Settlement and License Agreement with Merck for Anti-PD-1 Antibody Patent Infringement Litigation
|
|
Celyad
|
ONO enters into license agreement with Celyad for its allogeneic CAR T-cell therapy (NKR-2)
|
|
IDAC
|
ONO Enters an Agreement with IDAC Theranostics relating to Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody
|
|
2015
|
Santen
|
ONO Enters Licensing Agreement with Santen for ONO-9054, FP/EP3 Dual Receptor Agonist
|
|
2014
|
China Chemical & Pharmaceutical
|
ONO and CCPC enter into an agreement on development and commercialization of Limaprost in Taiwan
|
|
GILEAD
|
ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE TREATMENT OF B-CELL MALIGNANCIES AND OTHER DISEASES
|
|
Meiji Seika Pharma
|
Ono and Meiji Seika Pharma enter into an agreement on development and commercialization of Limaprost in Thailand and Indonesia
|
|
Bristol-Myers Squibb
|
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
|
|
2013
|
AstraZeneca
|
AstraZeneca and Ono Enter Co-promotion Agreement in Japan for Dapagliflozin
|
|
Valeant
|
Ono Enters into License Agreement with Valeant
|
|
Dainippon Sumitomo
|
Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China
|
|
Bial
|
Ono Enters into License Agreement with Bial
|
|
2011
|
Merck KGaA
|
Ono to Enter into License Agreements with Merck KGaA
|
|
Bristol-Myers Squibb
|
Ono and Bristol-Myers Squibb Enter into Strategic Agreement for Anti-PD-1 Antibody，ONO-4538／BMS-936558，and ORENCIA®（abatacept），Rheumatoid Arthritis Agent
|
|
KAI Phamaceuticals
|
Ono Enters into License Agreement with KAI Phamaceuticals，Inc．for KAI 4169
|
|
Servier
|
Ono Enters into License Agreement with Servier for Ivabradine
|
|
2010
|
OncoTherapy
|
Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines
|
|
Concordia
|
Ono Enters into License Agreement with Concordia for New Therapeutic Agent for Pancreatic Cancer
|
|
Onyx
|
Ono Announces Carfilzomib Development and Commercialization Agreement with Onyx Pharmaceuticals for Japan
|
|
2009
|
Tioga
|
License Agreement of a Drug Candidate for Irritable Bowel Syndrome with Tioga
|
|
2008
|
Progenics
|
Ono Enters into License Agreement with Progenics
|
|
2007
|
Nissan Chemical
|
Ono Enters into License Agreement with Nissan Chemical for New Therapeutic Agent for Thrombocytopenia
|
|
CeNeS
|
Ono Enters into License Agreement with CeNeS Limited - New Intravenous Anaesthetic -
|
|
2006
|
Sapphire
|
Ono Enters into License Agreement with Sapphire Therapeutics, Inc. in Japan,Korea and Taiwan - New Drug for the Treatment of Cancer Anorexia/Cachexia -
|
|
2005
|
Santen
|
Licensing Agreement on PDE4 Inhibitor ONO-6126
|
|
Novartis
|
Agreement on Joint Development and Marketing of Rivastigmine Transdermal Patch for the Treatment of Alzheimer's Disease
|
|
Merck
|
Results of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc. at ADA
|
